Brief: Instil Bio Reverse Stock Split Part Of Co's Plan To Regain Compliance With Minimum Bid Price
Instil Bio Inc reports results for the quarter ended in June - Earnings Summary
Instil Bio Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Instil Bio Announces Oral Presentation Of ITIL-306 Preclinical Data At British Society For Gene And Cell Therapy Annual Conference
Instil Bio Inc reports results for the quarter ended in March - Earnings Summary
Brief: Instil Bio Reports Q1 2023 Financial Results And Provides Corporate Update
Brief: Instil Bio Reports Q4 Loss Per Share Of $0.41
Instil Bio Inc reports results for the quarter ended in December - Earnings Summary
Brief: Instil Bio Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Corporate Update
Brief: Instil Bio Inc Informs Its Investors That It Does Not Hold Cash Deposits Or Securities At Silicon Valley Bank
Instil Bio Inc expected to post a loss of 41 cents a share - Earnings Preview
Brief: Instil Bio Board Approves An Expansion Of Its Previously Announced Realignment Plan
Brief: Instil Bio Announces Extension Of Cash Runway Beyond 2026
Brief: Instil Bio Received Notice Of Delisting From Nasdaq
U.S. STOCKS ON THE MOVE-Amazon.com, Paya Holdings, Bed Bath & Beyond
Instil Bio rises on resuming cancer therapy trial
Brief: Instil Bio Announces Resumption Of Clinical Trial Of CoStAR-TIL Candidate ITIL-306
U.S. RESEARCH ROUNDUP- Broadcom, Cooper Companies, Interdigital
Instil plunges after discontinuing trials, workforce reduction